GSK plc Delivers Strong Q3, Upgrades 2025 Guidance

TL;DR

GSK crushed Q3, sales hit £8.5B, raising 2025 outlook. Buy?

AI Summary

GSK plc reported strong Q3 2025 results, with total sales reaching £8.5 billion. The company has upgraded its full-year 2025 guidance, driven by growth in Specialty Medicines, Vaccines, and General Medicines. This performance indicates robust sales and profit growth for the pharmaceutical giant.

Why It Matters

This positive financial update suggests GSK is outperforming expectations, potentially leading to increased investor confidence and a stronger market position in the pharmaceutical sector.

Risk Assessment

Risk Level: low — The filing reports positive financial results and an upgraded guidance, indicating a stable and improving financial outlook for the company.

Key Numbers

• £8.5 billion — Q3 2025 Sales (Represents total sales for the third quarter of 2025.)

Key Players & Entities

• GSK plc (company) — Filer and reporting company
• £8.5 billion (dollar_amount) — Total Q3 2025 sales

FAQ

Key Financial Figures

• $1.34 — the closing rates on 30 September 2025 ($1.34/£1, €1.14/£1 and Yen 1

Filing Documents

• a1902f-gskoriginaledgar.htm (6-K) — 2215KB
• 0001654954-25-012307.txt ( ) — 2216KB

From the Filing

QUARTER RESULTS a1902f-gskoriginaledgar     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     GSK delivers strong Q3 performance and upgrades 2025 guidance   Specialty Medicines, Vaccines and General Medicines drive sales, profit and earnings growth ● Total Q3 2025 sales £8.5 billion +7% AER; +8% CER ● Specialty Medicines sales £3.4 billion (+16%); Respiratory, Immunology & Inflammation £1.0 billion (+15%); Oncology £0.5 billion (+39%); HIV sales £1.9 billion (+12%) ● Vaccines sales £2.7 billion (+2%); Shingrix £0.8 billion (+13%); Meningitis vaccines £0.5 billion (+5%); and Arexvy £0.3 billion (+36%) ● General Medicines sales £2.5 billion (+4%); Trelegy £0.7 billion (+25%) ● Total operating profit >100% and Total EPS >100% driven by lower Significant legal expenses, lower CCL charges and higher other operating income, partly offset by intangible asset impairments ● Core operating profit +11% and Core EPS +14% reflecting Specialty Medicines and Vaccines growth, higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines ● Cash generated from operations of £2.5 billion with free cash flow of £1.2 billion   (Financial Performance – Q3 2025 results unless otherwise 2025 and YTD 2025, the adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 11 for further details.)     Q3 2025   Year to date   £m   % AER   % CER   £m   % AER   % CER Turnover 8,547   7   8   24,049   3   6 Total operating profit 2,593   >100   >100   6,832   >100   >100 Total operating margin % 30.3%   28.0ppts   28.5ppts   28.4%   14.1ppts   14.5ppts Total EPS 49.9p   >100   >100   125.1p   >100   >100 Core operating profit 2,985   8   11   8,149   6   9 Core operating margin % 34.9%   0.4ppts   0.9ppts   33.9%   0.7ppts   1.0ppts Core EPS 55.0p   11   14   146.3p   7   11 Cash generated from operations 2,520   1       6,254   19       Pipeline progress and investment delivering future growth opportunities: 4 major new product approvals achieved so far this year: ● US & EU approvals for Blenrep for multiple myeloma, Penmenvy meningitis vaccine, Blujepa first-in-class antibiotic treatment for uUTIs and Nucala for COPD ● US decision on depemokimab (for asthma with type 2 inflammation, nasal polyps) expected in December 2025 15 scale opportunities with PYS potential >£2 billion now expected to launch 2025-2031: ● Pivotal trials started/to start by year-end for GSK'227 B7-H3 ADC for ES-SCLC; efimosfermin for treatment of MASH; depemokimab for COPD; and GSK '981 (IDRx-42) for 2L GIST ● Positive data support filings for tebipenem, potential new antibiotic for cUTIs; and Low Carbon Ventolin for asthma Targeted business development further strengthens RI&I and Oncology pipeline: ● Agreement with Empirico Inc. to acquire first - and potentially best-in-class - oligonucleotide candidate to treat respiratory diseases ● Licensing agreement with Syndivia for early-stage ADC targeting prostate cancer   Continued commitment to shareholder returns ● Dividend declared of 16p for Q3 2025; 64p expected for full year 2025 ● £1.1 billion spent in YTD 2025 as part of the £2 billion share buyback programme announced at FY 2024   2025 guidance upgraded Now expect: ● 2025 turnover growth of between 6% to 7% (previously towards the top end of the range of between 3% to 5%); ● Core operating profit growth of between 9% to 11% (previously towards the top end of the ra

View Full Filing

View this 6-K filing on SEC EDGAR